HASBROUCK HEIGHTS, N.J., April 24, 2012 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) is pleased to announce the presenters and participants for the symposium and panel discussion on NX-1207, the Company’s Phase 3 drug for benign prostatic hyperplasia (BPH), to be held during the 2012 Annual Meeting of the American Urological Association in Atlanta, GA 3:00 p.m. May 20. The Symposium will be held in the Georgia World Congress Center.
